Deep Genomics develops a machine learning technology to understand how genetic variations lead to diseases. It develops an integrated computational system that could learn, predict and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The Company offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome.
Deep Genomics, a Toronto genetic medicine startup, has raised $13 million in follow-on financing. Khosla Ventures led the round and was joined by True Ventures, which led the company’s $5 million seed financing in 2015. Spun out of the University of Toronto in 2014, Deep Genomics is building a biolo…